BioSpace News Archive

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022.

Windtree Therapeutics, Inc. reported that the United States Patent and Trademark Office has issued a Notice of Allowance of new patent claims for istaroxime administration.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR) today announced the European Commission (EC) has granted orphan designation for TMB-001 for the treatment of autosomal recessive congenital ichthyosis (ARCI).

Neurovative Diagnostics, a best-in-class industry leader providing in-home EEG testing and Continuous Monitoring services in acute care settings, announced a partnership with NeuroX, a physician-led, global telemedicine company and leading online clinic for neuro-psychology and neuroscience.

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today positive results from its proof-of-concept study for its diclofenac hydrogel patches.

Immutep Limited, a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 30 September 2022.

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”) today announced the issuance of a U.S. patent that protects the extension of the use of Biostage’s technology from hollow tubes to patches.

Glympse today announced that it will present a poster demonstrating that its novel protease biosensor diagnostic platform can detect hepatocellular carcinoma (HCC) at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2022, being held in Washington, D.C., from Nov. 4-8, 2022.

Aytu BioPharma, Inc. today announced an agreement with the Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Debt Fund” or “Avenue”) to extend the interest-only period of the Company’s existing senior secured loan facility held with Avenue.

Triumvira Immunologics today announced the appointment of Robert Williamson as President and Chief Business Officer.